BCU Wealth Advisors LLC Buys 177 Shares of Abbott Laboratories $ABT

BCU Wealth Advisors LLC lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 3.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,698 shares of the healthcare product maker’s stock after acquiring an additional 177 shares during the period. Abbott Laboratories makes up about 0.3% of BCU Wealth Advisors LLC’s investment portfolio, making the stock its 28th largest holding. BCU Wealth Advisors LLC’s holdings in Abbott Laboratories were worth $639,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently made changes to their positions in ABT. Hughes Financial Services LLC bought a new stake in shares of Abbott Laboratories during the first quarter worth $27,000. Abound Financial LLC bought a new stake in shares of Abbott Laboratories during the first quarter worth $28,000. Elequin Capital LP bought a new stake in shares of Abbott Laboratories during the first quarter worth $30,000. JCIC Asset Management Inc. bought a new position in Abbott Laboratories in the first quarter valued at $32,000. Finally, Vision Financial Markets LLC bought a new position in Abbott Laboratories in the first quarter valued at $33,000. Institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the subject of a number of analyst reports. Morgan Stanley raised their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Royal Bank Of Canada raised their target price on shares of Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Tuesday, July 15th. Raymond James Financial decreased their target price on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a research report on Friday, July 18th. Leerink Partnrs upgraded shares of Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Finally, Leerink Partners assumed coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They issued a “market perform” rating and a $143.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $145.22.

Abbott Laboratories Stock Performance

NYSE ABT opened at $133.01 on Tuesday. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The firm has a 50-day moving average of $131.31 and a 200-day moving average of $131.20. The stock has a market cap of $231.49 billion, a PE ratio of 16.67, a P/E/G ratio of 2.53 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. During the same quarter in the previous year, the company earned $1.14 EPS. The business’s revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories’s payout ratio is presently 29.57%.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.